Compare Suncor Energy Inc. (SU) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Suncor Energy Inc. vs Tango Therapeutics Inc. — how do they compare? Suncor Energy Inc. trades at $76.21 (market cap $88.76B), while Tango Therapeutics Inc. trades at $22.2 (market cap $3.74B). The key difference: Suncor Energy Inc. is far larger — about 23.7× Tango Therapeutics Inc.'s market cap, and Suncor Energy Inc. pays a 2.24% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Suncor Energy Inc. for 57 Days and Tango Therapeutics Inc. for 0 Days on average.
| SU | TNGX | |
|---|---|---|
Market Cap | $88.76B | $3.74B |
Volume | 2,892,643 | 3,438,781 |
Sector | Energy | Health |
52-Week High | $75.89 | $32.90 |
52-Week Low | $38.17 | $7.50 |
Typical Hold Time | 57 Days | 0 Days |
Enterprise Value | $95.31B | $2.76B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Suncor Energy (SU) trades at $75.2, up 2.3% today, near its recent highs. The stock shows strong technical momentum with bullish moving averages, though RSI levels suggest potential overbought conditions. Fundamentally, SU maintains solid profitability with a 14.7% net income margin and trades at a reasonable P/E of 14.32. Recent news highlights asset sales and shareholder returns, while analyst sentiment is overwhelmingly positive with 74% buy ratings.
Outlook: SU's integrated model and aggressive buybacks support upside, but reliance on commodity prices and operational risks pose challenges. The stock offers value with growth potential, yet investors should monitor oil price volatility and execution of strategic initiatives for sustained performance.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
